drugset / Trial / NCT00314782
Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Two-part, multi-center study design to establish a maximum tolerated dose (MTD) of ZD4054 in combination with docetaxel and to explore its safety, tolerability, pharmacokinetic (PK) profiles and clinical efficacy in patients with metastatic hormone-refractory prostate cancer (HRPC)
Timeline
- Start
- 2006-03
- Primary completion
- 2008-03
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zibotentan | Small molecule | 10 mg | Oral |
| Subject | Zibotentan | Small molecule | 15 mg | Oral |
| Background | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |